

Table captions

Table 1 Sugar acceptors used in this study

“√” means that the compound is able to react with OsUGT1; “×” indicates no reaction with OsUGT1

Table S2 The primers used in this study

Table S3 Plasmids and strains used in this research

Table S1

No	Sugar acceptor	CAS Number	Reaction
<i>Flavonoids</i>			
1	Sulfuretin	120-05-8	✓
2	Luteolin	491-70-3	✓
3	7,8-Dihydroxyflavone	38183-03-8	✓
4	5,7-Dihydroxyflavone	480-40-0	✓
5	6-Hydroxyflavone	6665-83-4	✓
6	3,2'-Dihydroxyflavone	6068-76-4	✓
7	5-Hydroxyflavone	491-78-1	×
<i>Anthraquinones</i>			
8	Rhein	478-43-3	×
<i>Steroids</i>			
9	Dehydroepiandrosterone	53-43-0	×
10	17 β -Estradiol	50-28-2	×
11	17 α -Estradiol	57-91-0	×
12	Methyltestosterone	58-18-4	×
13	Testosterone	58-22-0	×
14	15 β -Hydroxytestosterone	39605-73-7	×
15	2 β -Hydroxytestosterone	10390-14-4	×
16	16 β -Hydroxytestosterone	17528-90-4	×
17	16 α -Hydroxytestosterone	63-01-4	×
18	Cortisone	53-06-5	×
19	Hydrocortisone	50-23-7	×
20	β -Ecdysone	5289-74-7	×
21	Cholesterol	57-88-5	×
22	β -Sitosterol	83-46-5	×
23	Ergosterol	57-87-4	×
24	Diosgenin	512-04-9	×
25	Cholic acid	81-25-4	×
<i>Terpenoids</i>			
26	Protopanaxatriol	1453-93-6	×
27	Oleanolic acid	508-02-1	×
28	Ursolic acid	77-52-1	×
<i>Phenolic acids</i>			
29	Caffeic acid	331-39-5	×
30	Ferulic acid	1135-24-6	×
31	<i>p</i> -Coumaric acid	501-98-4	×
32	Sinapic acid	530-59-6	×
33	DL-4-Hydroxymandelic acid	1198-84-1	×
<i>Alkaloids</i>			
34	2,6-Dihydroxyquinoline	19315-93-6	×
35	Higenamine	5843-65-2	×

36	5-Hydroxyindole acetic acid	54-16-0	×
37	Berberine	2086-83-1	×
38	Camptothecin	7689-03-4	×
39	Securinine	5610-40-2	×
40	Matrine	519-02-8	×
41	Peimisine	19773-24-1	×

Table S2

Primer	Sequence (5'to 3')	Description
Fcomp28733-1	CAATCGTCTCCTCTTGGAC	Forward primer used for <i>OsUGT1</i> amplification in the first round
Rcomp28733-1	CATCAACTGATTGCTATGTC	Reverse primer used for <i>OsUGT1</i> amplification in the first round
Fcomp28733-2	ATGGAAGGGAAAAACAACAT	Forward primer used for <i>OsUGT1</i> amplification in the second round
Rcomp28733-2	TTACACAAAATCATGCAAAAG	Reverse primer used for <i>OsUGT1</i> amplification in the second round
F28a28733	CAAATGGGTCGCGGATCCGAATTCATGGAAGGGAAAAACAA	Forward primer used for the construction of pET28aOsUGT1
R28a28733	GTGCTCGAGTGCGGCCGCAAGCTTTCAGGTGACAACCCTTTT	Reverse primer used for the construction of pET28aOsUGT1

Table S3

Strains/plasmids	Description	Source/Reference
Strain		
<i>Trans1-T1</i>	F ⁻ ϕ80 (<i>lacZ</i>) ΔM15Δ <i>lacX</i> 74 <i>hsdR</i> (r _K ⁻ ,m _K ⁺) Δ <i>recA</i> 1398 <i>endA</i> 1 <i>tonA</i>	TransGen, Beijing, China
<i>Transetta</i> (DE3)	F ⁻ <i>ompThsdS</i> _{B(r_B⁻m_B⁻)<i>gal dcm</i> (DE3)pRARE(argU, argW,ilex,glyT,leuW,proL)Cam^r)}	TransGen, Beijing, China
Plasmid		
<i>pEASY</i> TM -Blunt	General cloning vector, T7 promoter, fl ori, Amp ^r and Kan ^r	TransGen, Beijing, China
pET-28a (+)	General expression vector, T7 promoter, fl ori, Kan ^r	Novagen, Madison, USA
<i>pEASY</i> -OsUGT1	<i>pEASY</i> TM -Blunt derived vector containing <i>OsUGT1</i> gene	This study
pET28a-OsUGT1	pET-28a (+) derived vector containing <i>OsUGT1</i> gene	This study

Figure legend

Figure S1 PCR product visualized on the agarose gel

PCR product amplified by nested PCR with (1) or without cDNA template (2). M represents molecular marker indicated on the left margin with bp.

Figure S2 List of conserved domain hits, PLN02863 (A), COG1819 (B) and MGT (C), using OsUGT1 as the query sequence.

Figure S3 Detection of the recombinant OsUGT1 by SDS-PAGE (A) and Western-blotting (B) .

Lane M; protein molecular weight marker; lane 1, the crude extract of *Transetta* (DE3) [pET28aOsUGT1] induced with IPTG; lane 2, the crude extract of *Transetta* (DE3) [pET-28a(+)] induced with IPTG; lane 3, the purified OsUGT1 protein; lane 4, western-blotting analysis of the crude extract containing the recombinant OsUGT1; lane 5, western-blotting analysis of the crude extract containing no OsUGT1

Figure S4 Mass spectra of metabolites **1a** (A), **1b** (B) and **1c** (C).

Figure S5 ^1H NMR spectrum (600 MHz, DMSO- d_6) (A) and ^{13}C NMR spectrum of **1a** (150 MHz, DMSO- d_6) (B)

Figure S6 HMBC spectrum of **1a**

Figure S7 ^1H NMR spectrum (600 MHz, DMSO- d_6) (A) and ^{13}C NMR spectrum of **1b** (150 MHz, DMSO- d_6) (B)

Figure S8 HMBC spectrum of **1b**

Figure S9 ^1H NMR spectrum (600 MHz, DMSO- d_6) (A) and ^{13}C NMR spectrum of **1c** (150 MHz, DMSO- d_6) (B)

Figure S10 HMBC spectrum of **1c**

Figure S11 HPLC chromatogram of glucosylation of luteolin (**2**) with OsUGT1 (a) or without OsUGT1 (b) (A). The UV absorption spectrum of glucosylated metabolites **2a-2c** is similar to that of **2**. All of them are marked in the upper panel.

Figure S12 The mass spectra of glucosylated metabolites **2a** (A), **2b** (B) and **2c**(C).

Figure S13 HPLC chromatogram of glucosylation of 7,8-dihydroxyflavone (**3**) with OsUGT1 (a) or without OsUGT1 (b) (A). The UV absorption spectrum of glucosylated metabolite **3a** is similar to that of **3**. Both are marked in the upper panel.

Figure S14 The mass spectrum of glucosylated metabolite **3a**.

Figure S15 HPLC chromatogram of glucosylation of 5,7-dihydroxyflavone (**4**) with OsUGT1 (a) or without OsUGT1 (b) (A). The UV absorption spectrum of glucosylated metabolite **4a** is similar to that of **4**. Both are marked in the upper panel.

Figure S16 The mass spectrum of glucosylated metabolite **4a**.

Figure S17 HPLC chromatogram of glucosylation of 6-hydroxyflavone (**5**) with OsUGT1 (a) or without OsUGT1 (b) (A). The UV absorption spectrum of glucosylated metabolite **5a** is similar to that of **5**. Both are marked in the upper panel.

Figure S18 The mass spectrum of glucosylated metabolite **5a**.

Figure S19 HPLC chromatogram of glucosylation of 3,2'-dihydroxyflavone (**6**) with OsUGT1 (a) or without OsUGT1 (b) (A). The UV absorption spectrum of glucosylated metabolites **6a** and **6b** is similar to that of **6**. All of them are marked in the upper panel.

Figure S20 The mass spectra of glucosylated metabolites **6a** (A) and **6b** (B).




Figure S1






Figure S2




Figure S3




Figure S4





Figure S5






Figure S7




Figure S8





Figure S9







Figure S11




Figure S12




Figure S13




Figure S14




Figure S15




Figure S16





Figure S17




Figure S18




Figure S19





Figure S20